Realyze Intelligence, which uses a similar approach in cancer, was purchased by Carta Healthcare, whose software platform uses artificial intelligence (AI) to reduce the time and expenses associated with data abstraction for both structured and unstructured data.

Carta Healthcare, a San Francisco-based company founded in 2019, says to use both artificial intelligence and skilled clinical data abstractors to support a variety of health systems across the country, ranging from large academic medical institutions to independent community hospitals. Among its clients in the health system are Mass General Brigham, CommonSpirit, and Grady.

Established in 2020, Realyze Intelligence is a portfolio firm of UPMC Enterprises, which is UPMC’s innovation, commercialization, and venture capital division. To find the best candidates for clinical trials and other research projects, our program examines both structured and unstructured data in electronic health records. Instead of taking hours or days to complete manually, the company claims that its clinician-trained AI can put together suitable cohorts in a matter of seconds. Cancer centers use Realyze Intelligence, which is a component of the Innovation Hub of Memorial Sloan Kettering Cancer Center. Earlier this year, Realyze Intelligence was also chosen to be a part of the CancerX Accelerator Program’s first program.

The acquisition’s terms were not made public.

According to a Realyze Intelligence research, UPMC Hillman Cancer Center saw twice as many patients join and seven times as many people matched to studies when the software was used.

In a statement, Carta Healthcare CEO Brent Dover stated, “We think data is the single most important ingredient to improve healthcare.” Clinicians deal with overwhelming volumes of data, from clinical trials to clinical registries, that are brimming with important insights to enhance patient outcomes and care practices. We are motivated by Realyze Intelligence’s shared capability to optimize insights from clinical data for clinical trials and cancer registries by utilizing clinician-trained AI and a human-in-the-loop methodology.

“Health systems and pharmaceutical companies invest billions annually to identify and enroll patients for clinical trials—a process that is not only costly but labor-intensive and time-consuming,” said Aaron Brauser, founder and CEO of Realyze Intelligence, in a statement. “High-quality, timely data is essential for accurately identifying eligible patients, yet much of it remains trapped in EHRs and other systems. We are excited to revolutionize clinical trial matching and reuse the data to enhance research, optimize care pathways and improve patient outcomes with Carta Healthcare.”